Aeterna Zentaris, Ergomed deal

Aeterna partnered with CRO Ergomed to co-develop Zoptarelin doxorubicin acetate ( AEZS-108) to treat endometrial cancer. Ergomed will be responsible for 30% of the costs for a Phase III trial, which is slated to start this month. In turn, Ergomed is eligible for single-digit royalties on net income for Zoptarelin in the indication. Aeterna said the deal "does not affect [its] strategy of looking for out-licensing opportunities" for Zoptarelin, a doxorubicin chemotherapeutic conjugated to a luteinizing hormone-releasing hormone (LHRH) receptor agonist. ...